Janux Therapeutics, Inc. Impairment of Long-Lived Assets Held-for-use
Janux Therapeutics, Inc. (JANX) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2023-03-10
- Janux Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2022 was $0.00.
- Janux Therapeutics, Inc. impairment of long-lived assets held-for-use for fiscal 2021 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-10 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |